CAR T-Cell Therapy in India
In October 2023, the Central Drugs Standard Control Organization (CDSCO), which is India’s equivalent of the US Food and Drug Administration, granted approval to NexCAR19, making it the first CAR-T cell therapy to be licensed in India. CAR T Cell therapy in India has been officially launched in 6 hospitals across Delhi, Mumbai, and Pune.
In the past few years, Indian hospitals and study centres have come a long way towards using CAR T-cell therapy. CAR T-cell therapy could change the way cancer is treated, so it gives patients who don’t have many other choices new hope. In this new treatment, the patient’s own immune cells are reprogrammed to find and kill cancer cells.
CAR T-Cell Therapy Gudaha Hindiya - Xaalada Hadda
Febraayo, 2024: In October 2023, the Central Drugs Standard Control Organization (CDSCO), which is India’s equivalent of the US Food and Drug Administration, granted approval to NexCAR19, making it the first CAR-T cell therapy to be licensed in India. Daaweynta CAR T Cell ee Hindiya has been officially launched in 6 hospitals across Delhi, Mumbai, and Pune.
Shatiga waxaa la bixiyay iyadoo lagu saleynayo natiijooyinka laga helay laba tijaabo caafimaad oo xaddidan oo lagu sameeyay Hindiya oo ku lug leh wadar ahaan 64 qof oo laga helay lymphoma sare ama leukemia. Iyada oo ku saleysan natiijooyinka tijaabada ah ee lagu bixiyay shirkii Bulshada Maraykanka ee Dhiigbaxa Diseembar 2023, waxaa la arkay in 67% bukaannada (36 ka mid ah 53) ee ka qaybqaatay labada daraasadood ay la kulmeen hoos u dhac weyn oo ku yimid cabbirka kansarka (jawaab ujeedo leh). ). Qiyaastii kala badh bukaannadan waxay heleen wadarta guud ee la waayo xumaanta (jawaab dhamaystiran).
ImmunoACT, oo hoos timaada IIT Bombay, ayaa bixisay maalgelinta tijaabada waxayna mas'uul ka noqon doontaa soo saarista iyo ganacsiyeynta actalycabtagene autoleucel.
Apart from current ongoing clinical trials in ACTREC and Narayana, Bengaluru, MGRC has collaborated with a China-based CAR cell biotech company to bring CAR T-Cell therapy to India. At present, this life-saving therapy is available in the USA, UK, Canada, Israel, Singapore, China, Malaysia, & Australia. The cost of this therapy is around 5-7,00,000 USD in the USA, whereas in Shiinaha it costs anywhere between $70,000 iyo $80,000 USD.
Tijaabooyin caafimaad oo loogu talagalay CAR T- Daaweynta unugyada for the treatment of some types of kansarka dhiigga have kicked off at the Advanced Centre for Treatment, Research, and Education in Cancer, the research and development wing of Xarunta Tata Memorial. “More details of the trial will be revealed soon,” Dr. Narula said in a press brief. This tijaabada caafimaadka is taking place with the help of a researcher from IIT, Bombay, who has developed this life saving therapy.
Dr. Reddys lab has also secured a deal with Shenzen Biopharma Pregene of China on May 21 to bring this life-saving therapy to India. There are several other companies that are also working to bring this technology to India. US-based Indian-born oncologist Dr. Siddharth Mukherjee was in India recently and had a meeting with Kiran Mazumdar Shaw of Biocon & Mr. Kush Parmar of 5 AM Ventures. All of them have agreed to come up with a facility to grow a Chimeric Antigen Receptor (CAR) cells to fight cancer. As per the reports, this therapy can be available in India in about a year’s time. This therapy has recently been approved by FDA (Food and Drug Administration). This cell therapy is useful for treatment in certain children and young adults suffering from Non – Hodgkin lymphoma. Treatment with Yeskarta & Kymriah is the first CAR T-Cell therapy to receive FDA approval.
In kasta oo xaqiiqda ay jiraan tijaabooyin fara badan oo daaweyn unugyo ah oo firfircoon kana diiwaangashan Mareykanka, Midowga Yurub, iyo Shiinaha, midkoodna lagama helin Hindiya.
cusub ee Immuneel facility in Bengaluru’s Narayana Health City is dedicated to introducing high-quality and affordable cell therapies to India. The facility’s strategic location in a tertiary care hospital near a high-volume bone marrow transplant unit allows for further coordination between research teams and clinicians, which is important for focused clinical development of innovative personalized therapies like CAR-T.
Immuneel is working hard to advance its pipeline. The company’s strategy of licensing a CAR-T asset that has already been clinically tested is expected to result in the company’s first cell therapy clinical trial in 2021. In terms of laboratory and production facilities, including equipment and instruments, Immuneel’s integrated facility is among the best in the world. This helps physicians and scientists work together seamlessly both internally and with research institutes across the world on product creation and distribution. To support this target, the organization has attracted exceptional global talent with prior experience in cell therapy, as well as a distinguished Scientific Advisory Board consisting of the field’s most respected scientific and intellectual giants.
These therapies are labor-intensive, meticulously managed, require costly reagents and consumables, and are difficult to automate. The logistics of preserving and transporting cryopreserved cells continues to be a global problem. Because of all of these factors, cell therapies are exceedingly difficult to produce and supply and, thus, extremely costly. Cell therapies are difficult to prescribe clinically, and patients must be closely monitored for adverse events in the hospital immediately after infusion.
Natiijada Wajiga II CAR T-Cell Therapy Tijaabooyin Caafimaad oo gudaha Hindiya ah
At ASCO, Dec 22 shirka, Immuneel, bilawga daaweynta unugyada iyo hidda-wadaha, ayaa ku dhawaaqay in natiijooyinka hordhaca ah ee ka soo baxa Hindiya ee wejiga koowaad ee 2 tijaabooyinka bukaan-socodka ay muujiyeen 77% heerka jawaabta guud ee maalmaha 90 ee bukaanka qaba kansarka dhiigga sida leukemia iyo lymphoma. Immuneel wuxuu horumarinayaa daawaynta unugyada CAR-T Varnimcabtagene.
Natiijooyinka bilowga ah ee tijaabada IMAGINE waxay ku saleysan yihiin diiwaan gelinta 10-kii qof ee ugu horreeyay marka loo eego wadarta bukaannada 24.
Maalintii 28, in ka badan 80% bukaanada ayaa si buuxda uga soo kabtay caafimaad. Maalintii 90, xogta IMAGINE waxay daaha ka qaaday heerka jawaab celinta guud ee 77%, iyada oo jawaabo dhamaystiran lagu muujiyay 6 ka mid ah 9 bukaanada la qiimeeyo.
Maalinta 28-aad ee bukaannada leukemia-ga ba'an ee leukemia-ga iyo maalinta 90-aad waxay muujinayaan 100% iyo 83% cafis dhammaystiran, siday u kala horreeyaan, taasoo muujinaysa jawaabo degdeg ah, xooggan, iyo jawaabo waara.
Varnimcabtagene waxay qaadatay 12 maalmood celcelis ahaan in la soo saaro oo la sii daayo, iyada oo 100% heerka guusha wax soo saarka.
Kiran Mazumdar-Shaw, gudoomiyaha Biocon, Siddhartha Mukherjee, khabiir ku takhasusay kansarka iyo qoraaga caanka ah, iyo Kush Parmar, oo ah maamulaha shirkadda 5AM Venture, oo la aasaasay Imuneel. Imuneel waxa ay horumarinaysaa tubbo u gaar ah oo ah daawaynta T-cell (CAR-T) iyo kuwa kale ee difaaca unugyada ee daawaynta kansarka.
Waa maxay Baaxadda Daaweynta Unugyada Car-T ee Hindiya?
Hordhac: Daaweynta CAR T-cells waa nooc cusub oo daaweyn ah oo bedelaya sida kansarka loola dhaqmo adduunka oo dhan. Dhowrkii sano ee la soo dhaafay, Hindiya waxay samaysay horumar badan oo ku saabsan qaadashada daaweyntan goynta ah, taasoo siinaysa bukaanada qaba noocyada kala duwan ee kansarka sababo cusub oo rajo ah. Daaweynta unugyada CAR-T waxay u badan tahay inay saameyn weyn ku yeelato daryeelka caafimaadka Hindiya sababtoo ah waxay bedeli kartaa habka loo daaweeyo kansarka.
Kordhinta Ikhtiyaarada Daawaynta: Imaatinka daaweynta unugyada CAR-T ee Hindiya waxay siisay bukaannada habab badan oo lagu daweyn karo, gaar ahaan kuwa qaba kansarka dhiigga sida leukemia iyo lymphoma. Daaweyntani waxay ku lug leedahay soo saarida unugyada T ee bukaanka, beddelidda hidde ahaan si ay u soo saaraan chimeric antigen reseptors (CARs) kuwaas oo bartilmaameedsada unugyada kansarka, ka dibna dib ugu celisa jirka bukaanka. Daawaynta unugyada CAR-T waa hab la shakhsiyeeyay oo u sahlaya habdhiska difaaca inuu helo oo dilo unugyada kansarka.
Cilmi-baarista iyo horumarinta: R&D has come a long way. India has a strong infrastructure for research and development, and top institutions and hospitals are actively looking into the potential of CAR-T cell therapy. This dedication to study has led to exciting new developments, such as the creation of CAR-T cell therapies that are tailored to the unique genetic and ethnic diversity of the Indian people. These kinds of improvements help to broaden the therapy’s reach and make it possible to use it on more types of cancer.
La awoodi karo iyo helitaan: Mid ka mid ah waxyaabaha ugu wanaagsan ee ku saabsan daaweynta unugyada CAR-T ee Hindiya ayaa ah, marka loo eego qaar ka mid ah waddamada reer galbeedka, waa mid la awoodi karo. Bukaannada ka kala socda qaybaha kala duwan ee nolosha waxay u badan tahay inay awoodaan inay awoodaan sababtoo ah qiimuhu waa yar yahay waxaana jira doorashooyin badan oo daaweyn ah. Sidoo kale, tiro isbitaallo iyo xarumo caafimaad oo Hindi ah ayaa la shaqeeyay shirkado caalami ah oo dawooyinka ka shaqeeya si ay u keenaan daweynta unugyada CAR-T Hindiya, taasoo u sahlaysa dadka u baahan inay helaan.
Caqabadaha iyo Rajada Mustaqbalka: Daawaynta unugga CAR-T waxay leedahay awood badan, laakiin sidoo kale waxay leedahay dhibaatooyin. Dhibaatooyinka u baahan in la xalliyo waxaa ka mid ah kharashka badan ee daawaynta, dhibaatada samaynta daawada, iyo baahida qalab gaar ah. Laakiin dawladda Hindiya, oo la shaqaynaysa daneeyayaasha daryeelka caafimaadka, ayaa si adag uga shaqaynaysa sidii ay u xallin lahayd dhibaatooyinkan oo ay u dejisay nidaam sharciyeed daawaynta si loogu isticmaalo si badbaado leh oo waxtar leh.
Isticmaalka daaweynta unugyada CAR-T ee Hindiya ayaa si dhakhso ah u koraya, taasoo siinaysa bukaanka kansarka rajo cusub iyo habab wanaagsan oo lagu daweeyo cudurkooda. Hindiya waa meel wanaagsan oo loogu talagalay daawaynta asaasiga ah sababtoo ah waxaa ka go'an in ay wax barato, qiimuhu waa hooseeyaa, iyo helitaanka ayaa soo fiicnaanaya. Maaddaama nidaamka daryeelka caafimaad ee Hindiya uu sii socdo isbeddelka, ku-darka daawaynta unugyada CAR-T waxay u badan tahay inay beddelaan habka loola dhaqmo kansarka, wax u roonaanta bukaanka iyo beddelidda nolosha.
Where is CAR T Cell therapy available in India?
You can find CAR T-Cell therapy in several prominent Indian medical healthcare centers, such as Tata Memorial Centre, Apollo Cancer Hospital, BLK, Artemis, Asian Oncology, American Oncology, and HCG.
Helitaanka CAR T Cell Therapy ee xarumahan daryeelka caafimaadka ee sharafta leh waa tallaabo aad u weyn dagaalka Hindiya kula jirto kansarka. Soo hel 5ta cosbitaal ee ugu sareeya ee caan ku ah bixinta kuwa ugu fiican CAR-T treatment in India.
Tata Memorial Cancer Hospital ee Mumbai
Ka mid ah bixiyayaasha hormuudka ah ee CAR T Daaweynta Hindiya, first comes Tata Memorial Hospital, which is a world-class cancer treatment provider. In this hospital, a team of experienced doctors and researchers work hard to fight cancer using advanced treatments. The hospital is known for its excellence in cancer care and has a lot of experience in using CAR T Cell therapy to help patients get better. People come here from all over because they trust Tata Memorial to give them the best chance at beating cancer. So, if you or someone you know needs excellent cancer care, Tata Memorial Cancer Hospital is a great choice.
Machadka Kansarka Apollo ee Chennai
Machadka Kansarka Apollo ee Chennai waa xarun daryeel caafimaad oo caan ah oo caan ku ah adeegyada daaweynta kansarka ee heer sare ah. Waxay bixiyaan daryeel dhamaystiran bukaanka kansarka iyada oo loo marayo tignoolajiyada horumarsan iyo koox khibrad sare leh oo ku takhasusay kansarka. Kooxdooda gaarka ah ee dhakhaatiirta kansarka, dhakhaatiirta qalliinka, iyo shaqaalaha taageerada waxay u shaqeeyaan si aan daalin si ay u abuuraan qorshooyin daawaynta shakhsi ahaaneed kuwaas oo mudnaanta siinaya waxtarka iyo tayada nolosha bukaanka labadaba. Ka go'naanshahooda heer sare waxay kasbadeen sumcad la ixtiraamo xagga daryeelka kansarka.
Machadka Qaranka ee Kansarka (AIIMS) ee Delhi
Machadka Qaranka ee Kansarka (AIIMS) ee Delhi waa machad kale oo hormuud u ah daaweynta unugyada CAR-T. Waxaad ka heli kartaa daawaynta CAR-T halkan oo ah qiimaha ugu jaban. Machadkan caafimaad waxa uu caan ku yahay cilmi-baadhistiisa horumarsan ee ku saabsan daawaynta unugyada difaaca jirka, tas-hiilaadka ugu sarreeya, iyo dhakhaatiir xirfad sare leh. Xaruntu waxa ay qaadaa hab kooxeed, iyada oo isu keenta dhakhaatiirta khibrada leh ee kansarka, dhakhaatiirta qalliinka, dhakhaatiirta shucaaca, iyo shaqaalaha taageerada si ay u abuuraan qorshooyinka daawaynta shakhsi ahaaneed ee kansarka dhiigga iyo sidoo kale dhammaan noocyada kale ee kansarka. Waxay xitaa isticmaalaan tignoolajiyada horumarsan sida sirdoonka macmal ah iyo falanqaynta hidde-sideyaasha si ay u siiyaan daryeelka kansarka ugu fiican bukaanka.
BLK Max Xarunta Kansarka, Delhi
The BLK Max Cancer Centre in Delhi is one of India’s leading cancer hospitals, dedicated to providing chimeric antigen receptor t cell therapy (CAR T). Their institute has advanced technology for cancer care, which includes robotic surgery, tomo therapy, and immunotherapy. Their warm and supportive environment can help you stay strong and combat the disease.
Rajiv Gandhi Machadka Kansarka & Xarunta Cilmi-baarista ee Delhi
Machadka Kansarka Rajiv Gandhi & Xarunta Cilmi-baarista ee Delhi waa mid ka mid ah xarumaha kansarka ee Aasiya. Farsamooyinkooda hal-abuurka leh iyo shaqaalahooda kartida leh waxay bixiyaan daryeel heer caalami ah oo loogu talagalay bukaannada Hindiya, iyo sidoo kale waddamada SAARC. Machadku wuxuu lahaa sharaf inuu si togan u saameeyo nolosha qiyaastii 2.75 lakh bukaanka kansarka tan iyo markii la aasaasay 1996. Khabiirkoodu wuxuu bixiyaa daryeelka ugu wanaagsan ee suurtogalka ah bukaanka kansarka iyada oo loo marayo daawaynta unugyada CAR T ee kharashka-ku-ool ah ee Hindiya.
La kulan Dhakhaatiirta Kansarka ee Sare ee CAR T daawaynta Unug ee Hindiya
Wax ka baro dhakhaatiirta kansarka ee ugu sarreeya CAR T Daaweynta Hindiya. Dhakhaatiirtan khibradda leh waxaa ka go'an inay bixiyaan daawaynta unugga ugu fiican ee kansarka oo ay weheliso daryeel iyo taageero shaqsiyeed. Ku kalsoonow khibradooda mustaqbal ifaya oo la dagaalanka kansarka!
Dr T Raja (MD, DM)
Dr. T Raja waa dhakhtar caan ku ah Oncologist oo khibrad 25 sano ka badan u leh daaweynta kansarka. Waxa uu caan ku yahay aqoontiisa sare waxaana loo arkaa mid ka mid ah dhakhaatiirta ugu sarreeya Hindiya. Dr. Raja waxa kale oo uu haystaa jago tacliimeed oo caan ah, isaga oo hogaaminaya barnaamijka DNB Medical Oncology ee Cisbitaalka Takhasuska leh ee Apollo ee Chennai. Waa haldoor aad loogu doondoono shirarka heer qaran iyo heer caalami, halkaas oo uu kula wadaago aragtidiisa qiimaha leh.
Dr Srikanth M (MD, DM)
Dr. Srikanth M. waa khabiir ku takhasusay dhiig-baxa Chennai, oo caan ku ah khibradiisa daaweynta xaaladaha kala duwan ee dhiigga. Waxa uu ku takhasusay arrimaha caafimaadka muddada-gaaban iyo kuwa muddada-dheer labadaba sida dhiig-yarida, myeloma, lymphomas-b-cell iyo leukemia. Dr. Srikanth M. waxa kale oo ay bixisaa baadhitaano horumarsan si loo eego caafimaadkaaga guud, sida hamiga dhuuxa lafta iyo daawaynta chelation ee xaaladaha dhifka ah sida macdanta xad dhaafka ah ee dhiiga. Dr. Srikanth M. waxa uu helay abaal-marinno ku mutaystay wax-ka-qabashada cilmi-baadhista myeloma, isaga oo ka dhigaya khabiir lagu kalsoon yahay oo ku takhasusay dhiig-baxa oo diyaar u ah in uu daryeel gaar ah siiyo bukaannada u baahan.
Dr Revathi Raj (MD, DCH)
Dr. Revathi Raj waa khabiir aad loo ixtiraamo oo loo yaqaan khibradeeda ku-tallaalidda dhuuxa lafta carruurta. Waxay si guul leh u samaysay in ka badan 2000 oo ka mid ah tallaaladan, taasoo ka dhigaysa khabiirkeeda hormuudka ah ee Hindiya. Dr. Raj waxa uu khibrad dheer u leeyahay daawaynta carruurta qaba cilladaha dhiigga sida thalassaemia, hemophilia, sickle cell anemia, aplastic anemia, iyo leukemia. Waxay aad ugu heellan tahay wanaagga carruurta, iyada oo wadda adeeg gaar ah oo loogu talagalay leukemia-da carruurta iyo lymfoma oo leh 80% heerka daawaynta.
Cost Of Car T-Cell Treatment In India
Oktoobar 13, 2023, shirkad lagu magacaabo Immunoadoptive Cell Therapy Private Limited (ImmunoACT) oo ku taal Mumbai ayaa ogolansho ka heshay Ururka Xakamaynta Maandooriyaha Dhexe (CDSCO) daawaynta kansarka gaarka ah ee Hindiya ee ugu horreysa ee loo yaqaan NexCAR19.
Daaweyntan waxaa si gaar ah loogu talagalay in lagu caawiyo dadka qaba noocyada leukemia iyo lymphoma qaarkood kuwaas oo aan ka jawaabin daaweynta kale. Tijaabada caafimaad ee habkan ayaa lagu sameeyay 60 bukaan oo qaba lymphomas iyo leukamia. Heerka jawaabta guud ee tijaabadan caafimaad ee muhiimka ah waxay ahayd 70% taasoo calaamadisay inay tahay daawayn guulaysata si loo burburiyo unugyada kansarka si wax ku ool ah.
The Qiimaha daaweynta unugyada CAR T ee Hindiya is approximately USD 57,000. This price is much lower when compared to countries like the USA, Singapore, Malaysia etc. However, it’s crucial to note that this pricing can vary depending on a variety of factors. The CAR-T cell therapy costs might differ from one hospital to another depending on their technology, expertise, and other facilities.
Furthermore, the type of CAR T-cell therapy required and the condition of the patient may also affect the overall cost.
Waa maxay Baabuurka T-Cell Therapy?
Chimeric antigen reseptor T-cell therapy, oo inta badan loo yaqaan CAR T-cell therapy, waa immunotherapy-jabin ah oo gebi ahaanba beddelay habka loo daweeyo kansarka. Waxay siisaa bukaanada qaba kansarrada qaarkood rajo oo markii hore loo arki jiray inay yihiin kuwo aan la daweyn karin ama leh dhowr dawo oo daaweyn ah.
Daawadu waxay ka kooban tahay isticmaalka unugyada difaaca jirka ee bukaanka - si gaar ah, unugyada T-iyo shaybaadhka wax ka beddelka iyaga si kor loogu qaado awooddooda si ay u ogaadaan oo ay u burburiyaan unugyada kansarka. Si taas loo sameeyo, unugyada T-da waxa la siiyaa reseptor-ka-kimeric antigen (CAR), kaas oo siinaya awood ay ku beegsadaan borotiinno gaar ah, ama antigens, oogada unugyada kansarka.
Unugyada T ee bukaanka ayaa marka hore laga saaraa, ka dibna si hidde ahaan wax looga beddelo si ay u muujiyaan CAR. Shaybaadhka, unugyadan la beddelay ayaa la badiyo si ay u soo saaraan tiro badan oo ah unugyada CAR T, kuwaas oo dib loogu celiyo dhiigga bukaanka.
Isla marka ay gudaha jidhka ku jiraan, unugyada CAR T waxay helayaan unugyo kansar oo muujiya antigen-ka la rabo, ku dheggan, oo kiciya jawaab celin difaac oo xooggan. Unugyada CAR T ee la hawlgeliyay way bataan oo waxay weerar ku qaadaan unugyada kansarka, iyaga oo dila.
Marka loo isticmaalo daawaynta cudurrada dhiigga qaarkood sida leukemia ba'an ee lymphoblastic (ALL) iyo noocyada gaarka ah ee lymphoma, daawaynta CAR T-cell waxay muujisay natiijooyin aan caadi ahayn. Waxay soo saartay heerar jawaab celin oo muuqda iyo bukaannada qaarkood, xitaa cafisyo waara.
Daawaynta CAR T-cell, si kastaba ha ahaatee, waa hab daawayn casri ah oo gaar ah oo laga yaabo inay leedahay khataro iyo saamayn xun. Cytokine release syndrome (CRS), falcelin difaaceed baahsan oo ka dhalan karta calaamado hargab oo kale ah iyo, xaaladaha daran, xubnaha oo fashilma, waxaa laga yaabaa inay la kulmaan dadka qaarkood. Waxa kale oo jiray warbixino ku saabsan saamaynta xun ee neerfaha, si kastaba ha ahaatee inta badan waa la daweyn karaa.
Iyadoo ay jiraan dhibaatooyinkaas, daaweynta CAR T-cell waa horumar la taaban karo oo laga gaaray la dagaallanka kansarka waxayna muujineysaa karti weyn mustaqbalka. Daraasadaha hadda jira waxay diiradda saarayaan kor u qaadista waxtarkeeda iyo astaanta badbaadada iyo sidoo kale fidinta isticmaalkeeda noocyada kansarka ee kala duwan. Daaweynta CAR T-cell waxay awood u leedahay inay beddesho wajiga daaweynta kansarka oo ay siiso bukaannada meel kasta oo ay joogaan rajo cusub oo horumar dheeraad ah leh.
Nidaamka
Habka daawaynta CAR-T, oo qaadata dhowr toddobaad, waxay ku lug leedahay tillaabooyin badan:
Unugyada T waxaa laga soo saaraa dhiiggaaga iyadoo la isticmaalayo tuubo la geliyo xididka cududda. Tani waxay qaadataa dhowr saacadood.
Unugyada T waxaa loo qaadaa xarun ay ku maraan beddelka hidde-sidaha si ay u noqdaan unugyo CAR-T. Laba ilaa saddex toddobaad ayaa ku dhammaanaya tan.
Unugyada CAR-T ayaa dib loogu soo celinayaa dhiiggaaga iyadoo loo marayo dhibic. Tani waxay u baahan tahay dhowr saacadood.
Unugyada CAR-T waxay beegsadaan oo tirtiraan unugyada kansarka ee jirka oo dhan. Ka dib markaad hesho daawaynta CAR-T, si dhow ayaa laguula socon doonaa.
Nooca Unugyada Kansarka Ayaa Lagu Daweyn Karaa Daaweynta Unugyada Car-T?
Kaliya bukaanada qaba kansarka qanjirka 'B-cell' ee Hodgkin's ama lymphoblastic leukemia ee ba'an ee carruurta kuwaas oo horey u tijaabiyay laba daaweyn oo caadi ah oo aan guulaysan ayaa hadda isticmaali kara alaabada daaweynta CAR T-cell ee helay oggolaanshaha FDA. Si kastaba ha ahaatee, daawaynta CAR T-cell ayaa hadda lagu tijaabiyay daraasadaha kiliinikada sida daawaynta safka koowaad ama labaad ee lymphoma dadka waaweyn iyo kansarka carruurta ee lymphoblastic leukemia. Dhawaan, qaar ka mid ah daraasadaha ayaa muujiyay guulo la taaban karo oo laga gaaray xaaladaha burooyinka adag sida glioblastoma, gliomas, kansarka beerka, kansarka sambabada, kansarka GI, kansarka ganaca iyo kansarka afka.
Gunaanad
Tani waxay ka dhigan tahay horumar la taaban karo oo laga sameeyay maaraynta leukemia iyo lymphoma B-cell. Intaa waxa dheer, waxa ay rajo gelinaysaa kuwa hore loo saadaaliyay in noloshooda ay ku jirto lix bilood oo keliya. Hadda oo aanu aqoonsannay hababka wax-iska-caabbinta oo aanu abuurnay farsamooyin badan oo lagula dagaallamo, mustaqbalka waxa uu u muuqdaa mid aad u rajo badan.
Kala xidhiidh bixiyeyaashayada daryeelka caafimaadka ee khibradda sare leh halkan Faa'iidada Kansarka la tashi bilaash ah si loo sameeyo qorshe daryeel oo ku habboon baahiyahaaga daryeelka caafimaadka. Fadlan u soo dir warbixinnadaada caafimaad info@cancerfax.com ama WhatsApp ku + 1 213 789 56 55.
Waa maxay Faa'iidooyinka Daaweynta Unugyada Car-T?
Faa'iidada ugu weyni waa in daaweynta CAR T-cell ay u baahan tahay hal faleebo oo badanaa waxay u baahan tahay laba toddobaad oo keliya oo ah daryeelka bukaan-jiifka. Bukaanka qaba lymphoma non-Hodgkin iyo leukemia carruurta ee hadda la helay, dhanka kale, caadi ahaan waxay u baahan yihiin kiimoterabi ugu yaraan lix bilood ama ka badan.
Faa'iidooyinka daaweynta CAR T-cell, oo runtii ah dawo nool, waxay sii jiri kartaa sanado badan. Haddi iyo marka ay soo noqodku dhacdo, unugyadu wali way awoodi doonaan inay aqoonsadaan oo ay beegsadaan unugyada kansarka sababtoo ah waxay ku noolaan karaan jidhka muddo dheer.
Inkasta oo macluumaadka uu weli soo korayo, 42% bukaannada lymphoma ee qaangaarka ah ee lagu sameeyay daawaynta CD19 CAR T-cell ayaa weli ku jira cafis 15 bilood ka dib. Lix bilood ka dib, saddex-meelood laba meel bukaannada qaba kansarka leukemia ee ba'an ee carruurta ayaa weli ku jiray cafis. Nasiib darro, bukaannadani waxay lahaayeen burooyin aad u daran kuwaas oo aan si guul leh loo daweyn iyadoo la adeegsanayo heerarka daryeelka dhaqameed.
Bukaanno noocee ah ayaa noqon lahaa kuwa si wanaagsan u qaata daawaynta unugyada CAR-T?
Bukaanada da'doodu u dhaxayso 3 Sano ilaa 70 Sano ayaa lagu tijaabiyay daawaynta CAR T-cell ee noocyada kala duwan ee kansarka dhiiga waxaana la ogaaday in ay aad waxtar u leedahay. Xarumo badan ayaa sheegtey heerarka guusha ee in ka badan 80%. Musharaxa ugu wanagsan ee daawaynta unugyada CAR T-cell wakhtigan waa ilmo yar oo qaba lymfoblastic leukemia ba'an ama qof weyn oo qaba lymphoma B-cell oo daran kaas oo horey u lahaa laba xariiq oo daaweyn aan waxtar lahayn.
Ka hor dhamaadka 2017, ma jirin heer la aqbalay daryeelka bukaanka kuwaas oo horay u soo maray laba xariiq oo daawaynta ah iyada oo aan la kulmin cafis. Daawaynta kaliya ee FDA-ansixisay ee ilaa hadda la caddeeyey inay faa'iido weyn u leedahay bukaankan waa daawaynta CAR T-cell.
Sidee waxtar u tahay daawaynta unugyada Car-T?
Daawaynta CAR T-cell ayaa aad waxtar u leh daaweynta noocyada kansarka dhiigga qaarkood, sida lymphoblastic leukemia ba'an (ALL) iyo lymphoma non-Hodgkin. Tijaabooyinka kiliinikada, heerka jawaab celinta ayaa aad u wanaagsanaa, bukaanno badan ayaa galay cafis buuxa. Xaaladaha qaarkood, dadka isku dayay dawo kasta waxay heleen cafis waara ama xataa daawooyin suurtagal ah.
Mid ka mid ah waxyaabaha ugu wanaagsan ee ku saabsan daaweynta CAR T-cell waa inay beegsato unugyada saxda ah. Qabayaasha CAR ee lagu daray unugyada T waxay heli karaan calaamado gaar ah unugyada kansarka. Tani waxay suurtogal ka dhigaysaa in la bixiyo daawaynta la beegsaday. Habkan la beegsanayo waxa ay wax u dhimaysaa unugyada caafimaadka qaba sida ugu yar ee suurtogalka ah waxana ay hoos u dhigtaa halista waxyeelooyinka ka yimaada daawaynta dhaqameed sida kiimoterabiga.
Laakiin waxaa muhiim ah in maskaxda lagu hayo in daawaynta CAR T-cell ay wali tahay aag cusub oo wali isbedelaysa. Cilmi-baarayaasha iyo takhaatiirta ayaa si adag u shaqeynaya si ay u xalliyaan dhibaatooyinka sida kharashka badan, suurtagalnimada waxyeellooyin halis ah, iyo xaqiiqda ah in ay u shaqeyso oo kaliya noocyada kansarka qaarkood.
Dhammaadkii, daawaynta CAR T-cell waxay muujisay inay tahay hab aad loogu guulaysto in lagu daweeyo noocyada kansarka dhiigga qaarkood. Inkasta oo ay tahay hab rajo leh oo awood leh, daraasado badan iyo tijaabooyin caafimaad ayaa loo baahan yahay si loo hagaajiyo loona helo habab cusub oo loo isticmaalo. Daaweynta CAR T-cell waxay bedeli kartaa sida loo daweeyo kansarka oo wax u roonaan kara dadka adduunka oo dhan haddii ay sii fiicnaanayso.
Ku darida & Shuruudaha Ka Saarida
Shuruudaha ka mid noqoshada CAR T-Cell Therapy:
1. Bukaanada qaba CD19+ B-cell Lymphoma (Ugu yaraan 2 nidaamyadii hore ee kiimoteraabiga ee la isku daray)
2. Inaad gaarto 3 ilaa 75 sano
3. Dhibcaha ECOG ≤2
4. Haweenka leh awoodda dhalmo waa inay yeeshaan kaadi uurka baaritaanka la qaaday oo la caddeeyey inuu yahay mid taban daaweynta ka hor. Dhamaan bukaanada waxay isku raaceen inay isticmaalaan habab lagu kalsoonaan karo ee ka hortaga uurka inta lagu jiro mudada tijaabada iyo ilaa dabagal lagu sameeyo waqtiga ugu dambeeya.
Shuruudaha Ka-reebista ee CAR T-Cell Therapy:
1. Dhiig-kar gudaha ah ama miyir-beel
2. Neefsashada oo xumaata
3. Xinjirowga xididdada dhiigga ku faafa
4. Hematosepsis ama Infekshan firfircoon oo aan la xakamayn
5. Xakamayn la'aan sonkorow
Waa maxay Saamaynnada Daawaynta Unugyada Car-T?
Hoos waxaa ku xusan qaar ka mid ah waxyeelada daawaynta CAR T-cell.
- Cytokine release syndrome (CRS): Saamaynta ugu badan ee ugu badan ee suurtogalka ah ee daaweynta CAR T-cell waa cytokine release syndrome (CRS). Calaamadaha hargabka oo kale, oo ay ku jiraan qandho, daal, madax-xanuun, iyo murqo xanuun, waxaa keena wax-soo-saarka cytokines-ka T-ga ee la beddelay. Xaaladaha ba'an, CRS waxay keeni kartaa heerkul sare, hypotension, xubinta taranka, iyo xitaa cawaaqib halis ah.
- Sunta Neerfaha: Bukaanjiifka qaarkood waxaa laga yaabaa inay yeeshaan saameynaha neerfaha, kuwaas oo u dhexeeya darnaan laga bilaabo calaamado aan halis ahayn sida jahawareer khafiif ah iyo jahawareer ilaa kuwa ka sii daran sida suuxdin, delirium, iyo encephalopathy. Ka dib faleebada CAR T-cell, sunta neerfaha waxay badanaa dhacdaa usbuuca ugu horreeya.
- Cytopenia: Daawaynta CAR T-unuggu waxay keeni kartaa inay hoos u dhigto tirooyinka unugyada dhiigga, sida dhiig-yarida (tirada unugyada dhiigga cas ee hooseeya), neutropenia (tirada unugyada dhiigga cad oo hooseeya), iyo thrombocytopenia (tirada platelet oo hooseeya). Caabuqyada, dhiig-baxa, iyo daalku waxay ka mid yihiin khataraha ay uga sii dari karto cytopenia.
- Caabuqyada: CAR T-cell therapy's xakamaynta unugyada difaaca jirka ee caafimaadka qaba waxay kordhisaa halista caabuqyada bakteeriyada, fayraska, iyo fungal. Si looga hortago infekshannada, bukaanku waxay u baahan karaan in si dhow loola socdo oo la siiyo daawo ka hortag ah.
- Tumor Lysis Syndrome (TLS)Ka dib daaweynta CAR T-cell, waxaa suurtagal ah xaaladaha qaarkood in xaddi la taaban karo oo ka kooban unugyada lagu sii daayo dhiigga sababtoo ah dilka degdega ah ee unugyada burooyinka. Tani waxay keeni kartaa cillado dheef-shiid kiimikaad ah, sida potassium-ka xad-dhaafka ah, uric acid, iyo heerarka fosfateet, kuwaas oo dhaawici kara kelyaha oo sababi kara dhibaatooyin kale.
- Hypogammaglobulinemia: Daawaynta CAR T-cell waxay leedahay awood ay ku yarayso isku-darka unugyada difaaca jirka, taas oo keeni karta hypogammaglobulinemia. Tani waxay ka dhigi kartaa infekshannada soo noqnoqda inay u badan tahay waxayna wacdaa in la sii wado daawada beddelka unugyada.
- Sunta Xubinta: Daaweynta CAR T-cell waxay leedahay awood ay ku waxyeeleyso tiro xubno ah, oo ay ku jiraan wadnaha, sambabada, beerka, iyo kelyaha. Tani waxay u horseedi kartaa baaritaanada shaqada kelyaha ee aan caadiga ahayn, arrimaha neefsashada, arrimaha wadnaha, iyo baaritaanka shaqada beerka ee aan caadiga ahayn.
- Hemophagocytic lymphohistiocytosis (HLH): Cudur naadir ah laakiin suurtagal ah oo dilaa ah oo loo yaqaan hemophagocytic lymphohistiocytosis (HLH) ayaa ku soo bixi kara natiijada daawaynta CAR T-cell. Waxay ku lug leedahay firfircoonida xad-dhaafka ah ee unugyada difaaca jirka, taas oo keenta dhaawac halis ah xubnaha iyo bararka.
- Hypotension iyo Haysashada Dheecaannada: Natiijadu waxay tahay cytokines ay unugyada CAR T sii daayaan, bukaannada qaarkood waxaa laga yaabaa inay yeeshaan cadaadis dhiig oo hooseeya (hypotension) iyo xajinta dareeraha. Si wax looga qabto calaamadahan, tillaabooyin taageero ah oo ay ku jiraan dheecaannada xididka iyo dawooyinka ayaa loo baahan karaa.
- Xannaanada Labaad: Warbixinnada malignancies-ka labaad ee soo baxaya ka dib daaweynta CAR T-cell ayaa jira, inkastoo ay naadir yihiin. Cilmi baaris ayaa hadda lagu sameynayaa suurtagalnimada malignant-ka labaad iyo khataraha mustaqbalka fog.
Waxaa muhiim ah in la xasuusnaado in bukaan kastaa aanu yeelanayn dhibaatooyinkan soo raaca, iyo in qof walba heerka dareenkiisu uu kala duwanaan doono. Si loo yareeyo loona yareeyo saamaynta xun ee iman karta, kooxda caafimaadku waxay si dhow u baadhaan bukaanka ka hor, inta lagu jiro, iyo ka dib daawaynta CAR T-cell.
waqtigaas
Hoos ka hubi wadarta wakhtiga loo baahan yahay si loo dhamaystiro habka daawaynta CAR T-cell. In kasta oo wakhtiga xaddidan uu aad ugu xidhan yahay fogaanta shaybaadhka ee cusbitaalka diyaariyey CAR-da.
- Imtixaan & imtixaan: hal usbuuc
- Daawaynta kahor & Ururinta T-Cell: hal usbuuc
- Diyaarinta iyo soo celinta T-Cell: laba-saddex toddobaad
- Falanqaynta waxtarka 1aad: saddex toddobaad
- 2nd Waxtarka falanqaynta: saddex toddobaad.
Wadarta wakhtiga: 10-12 toddobaad
Sideen kuugu caawin karnaa inaad hesho daawaynta Kansarka ugu fiican Hindiya?
Helitaanka daaweynta kansarka ugu fiican ee Hindiya waxay noqon kartaa mid aad u adag, gaar ahaan haddii aad ka welwelsan tahay kharashka iyo sidoo kale tayada. Taasi waa meesha CancerFax kugu hagi karo sida saaxiib run ah!
Waxaan la soconaa in caafimaadkaagu uu aad u qiimo badan yahay iyo in wax u dhimista tayada daryeelku aanay ahayn ikhtiyaar. Taasi waa sababta aan si taxadar leh u dooranay dhakhaatiir khibrad sare leh oo aan la kaashanay isbitaallo dhowr ah oo ku yaal meelo kala duwan oo qiimo jaban si aad u hesho sida ugu habboon baahiyahaaga. Sidan, waxaad ku heli kartaa daryeel heer sare ah adigoon bangiga jebin. 10kii sano ee la soo dhaafay, habkayagu waxa uu horeba u caawiyay bukaanada ka kala yimid in ka badan 8 wadan oo waaweyn, waxaana naga go'an in aan kuu samayno sidaas oo kale. Nagu kalsoonow inaan ka helno daawaynta unug ee CAR T ee ugu fiican Hindiya.
Habka ugu Fudud ee Helitaanka Daaweynta Unug ee CAR T gudaha Hindiya
Soo dir warbixinahaaga
Nala wadaag taariikhdaada caafimaad, oo ay ku jiraan warbixinnada dhiigga ee dhawaa, natiijadii biopsy, iyo baaritaannada PET, nagula wadaag info@cancerfax.com. Tallaabadan muhiimka ah waxay noo ogolaanaysaa inaan qiimeyno xaaladaada oo aan kugu hago daawaynta ugu habboon.
Qiimaynta & Ra'yiga
Kooxdayada khubarada ah ayaa si taxadar leh u eegi doona warbixinahaaga si ay u bixiyaan qiimayn dhamaystiran iyo ra'yi khabiir. Tani waxay naga caawinaysaa inaan go'aamino habka ugu wanaagsan ee ficilka waxaanan kugula talineynaa cosbitaalada iyo dhakhaatiirta takhasuska leh ee ugu habboon daawaynta Unug CAR T sida ku cad miisaaniyadaada.
Visa Caafimaad iyo Safar
Waxaan kaa caawin doonaa inaad hesho fiisaha caafimaadka waxaanan qorsheyn doonaa qabanqaabada safarkaaga. Hadafkayagu waa inaan safarkaaga ka dhigno mid fudud sida ugu macquulsan si aad diiradda u saarto daaweyntaada iyo soo kabashadaada.
Daawaynta Iyo Dabagalka
Markaad timaaddo cisbitaalka aad dooratay, kooxdayada daacadda ah waxay sii wadi doonaan inay ku caawiyaan inta lagu jiro habka daaweynta. Waxaan kor u qaadeynaa xiriirka aan tooska ahayn ee adiga iyo shaqaalaha caafimaadka, annagoo hubinayna inaad hesho daawaynta ugu wanaagsan ee suurtogalka ah. Ladnaantaada ayaa weli ah mudnaantayada koowaad.
FAQs On Therapy T-Cell Baabuurka gudaha Hindiya
Waa maxay daaweynta CAR T-cell?
- Daawaynta CAR T-cell waa nooc ka mid ah daaweynta difaaca jirka oo ku lug leh wax ka beddelka unugyada T ee bukaanka si loo aqoonsado oo loo weeraro unugyada kansarka. Daawayntan shakhsi ahaaneed waxay muujisay natiijooyin rajo leh oo laga helayo noocyada kansarka qaarkood.
Daaweynta CAR T-cell ma laga heli karaa Hindiya?
- Haa, daawaynta CAR T-cell ayaa laga heli karaa Hindiya oo laga heli karaa qaar ka mid ah xarumaha kansarka ee gaarka ah. Si kastaba ha ahaatee, helitaankeedu wuu kala duwanaan karaa, waxaana laga yaabaa inay ku koobnaato noocyada kansarka qaarkood.
Kansarkee ayaa lagu daweyn karaa CAR T-cell therapy gudaha Hindiya?
- Laga bilaabo cusboonaysiintaydii ugu dambeysay, daawaynta CAR T-cell waxa ugu horrayn loo isticmaalay in lagu daweeyo noocyada kansarka dhiigga qaarkood, sida leukemia iyo lymphoma. Kansarrada gaarka ah ee u qalma daawaynta waxay ku xirnaan karaan borotokoolka ay raacaan xarumaha daryeelka caafimaadka ee gaarka ah.
Waa maxay kharashka daawaynta CAR T-cell ee Hindiya?
- Qiimaha daawaynta CAR T-cell waxay noqon kartaa mid sare. Waxa ku jiri kara kharashka ururinta iyo wax ka beddelka unugyada T ee bukaanka, hababka shaybaadhka, iyo maamulka daawaynta. Kharashku wuu kala duwanaan karaa iyadoo ku saleysan nooca kansarka ee la daweynayo iyo xarunta daryeelka caafimaadka.
Ma jiraan wax saameyn ah oo daawaynta CAR T-cell?
- Haa, sida daawaynta kasta, daawaynta CAR T-cell waxay yeelan kartaa waxyeelooyin. Dhibaatooyinka caadiga ah waxaa ka mid ah cytokine release syndrome (CRS) iyo sunta neerfaha. Darnaanta waxyeellooyinku way ku kala duwanaan karaan shakhsiyaadka dhexdooda.
Intee in le'eg ayay daawaynta CAR T-cell u tahay daawaynta kansarka?
- Daaweynta CAR T-cell waxay muujisay guul la taaban karo oo ku saabsan daaweynta noocyada kansarka qaarkood, gaar ahaan kansarka dhiigga. Si kastaba ha ahaatee, waxtarkeedu wuu kala duwanaan karaa iyadoo ku xiran nooca iyo marxaladda kansarka, iyo sidoo kale arrimaha bukaanka shakhsi ahaaneed.
Daaweynta CAR T-cell ma ku jirtaa caymis gudaha Hindiya?
- Daboolista caymisku way kala duwanaan kartaa. Waa lama huraan in aad ka hubiso bixiyaha caymiska iyo xarunta daryeelka caafimaadka ee bixisa daawaynta si loo fahmo fursadaha caymiska.
Sideen ku heli karaa daaweynta CAR T-cell gudaha Hindiya?
- Bukaanada xiisaynaya daaweynta CAR T-cell waa inay la tashadaan dhakhaatiirta kansarka iyo bixiyeyaasha daryeelka caafimaadka ee ku takhasusay daaweyntan. Waxay ku hagi karaan bukaanka habka qiimaynta waxayna go'aamin karaan u-qalmitaanka.